Table 3.
Multilevel Regression Predicting Primary GnRH Agonist Use
| Factor | Odds Ratio | 95% CI |
|---|---|---|
| Reimbursement generosity index | 1.00 | 1.00 to 1.00 |
| Practice type | ||
| Group practice | Reference | |
| Solo practice | 1.27 | 1.07 to 1.52 |
| Missing | 0.86 | 0.58 to 1.26 |
| Physician prostate panel size, prostate patients per year | ||
| < 20 | Reference | |
| 21-37 | 0.75 | 0.65 to 0.86 |
| ≥ 38 | 0.81 | 0.68 to 0.96 |
| T stage | ||
| T1 | Reference | |
| T2 | 1.91 | 1.72 to 2.13 |
| Grade | ||
| Well differentiated, 2-4 | Reference | |
| Moderately differentiated, 5-7 | 2.26 | 1.78 to 2.88 |
| Missing | 3.50 | 2.50 to 4.91 |
| No. of comorbidities | ||
| 0 | Reference | |
| 1 | 1.40 | 1.24 to 1.57 |
| 2 | 1.43 | 1.18 to 1.72 |
| ≥ 3 | 2.07 | 1.65 to 2.60 |
| Age, years | 1.78 | 1.38 to 2.30 |
| Age, squared | 1.00 | 1.00 to 1.00 |
| Race/ethnicity | ||
| Non-Hispanic white | Reference | |
| Non-Hispanic black | 1.42 | 1.17 to 1.73 |
| Hispanic | 1.25 | 1.00 to 1.56 |
| Other | 1.30 | 0.94 to 1.79 |
| Missing | 1.95 | 1.50 to 2.53 |
| Radiation oncology consultation | ||
| No | Reference | |
| Yes | 0.26 | 0.23 to 0.31 |
| Medical oncology consultation | ||
| No | Reference | |
| Yes | 0.88 | 0.65 to 1.19 |
| Urology consultation | ||
| No | Reference | |
| Yes | 5.62 | 3.19 to 9.90 |
| Primary care consultation | ||
| No | Reference | |
| Yes | 0.41 | 0.36 to 0.46 |
| Constant | 0.95 | 0.87 to 1.04 |
NOTE. Sample includes only patients (n = 15,128) of urologists who prescribed GnRH agonists. The model also adjusts for urologists’ length of time in practice, sex, training location, board certification status, medical school affiliation, proportion of minority patients in practice, patients’ marital status, rural residence, community educational attainment, community income, prior primary care use, year treated, and SEER region.
Abbreviation: GnRH, gonadotropin-releasing hormone.